Email this article Hemodynamic effects of the synthetic analogue of endogenous nitric oxide (II) donors a dinitrosyl iron complex in hypertensive patients with uncomplicated hypertensive crisis
- Authors: Gosteev AI.1, Zorin AV1, Rodnenkov OV1, Dragnev AG1, Chazov EI1
-
Affiliations:
- ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
- Issue: Vol 86, No 9 (2014)
- Pages: 49-55
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31557
- ID: 31557
Cite item
Full Text
Abstract
AIM. To examine the antihypertensive effect of the synthetic analogue of the endogenous nitric oxide donors in patients with grades 2-3 hypertension and uncomplicated hypertensive crisis (HC). MATERIALS AND METHODS. The study included 30 male patients aged 35 to 73 years (mean age 55.5±10.8 years). All the patients had grades 2-3 essential or secondary hypertension. Thirteen (43.3%) patients were observed to have signs of HC; 17 (56.7%) patients had persistent blood pressure (BP) elevation. A dinitrosyl iron complex was injected in a dose of 1.5 or 3 mg per kg of body weight. The purpose of its administration was to lower BP by at least 20% of its baseline level. RESULTS. No significant side effects associated with the administration of the test drug were recorded when the clinical trial protocol was implemented. All the patients reported fever and facial hyperemia during and 10-20 minutes after injection. They all (100%) showed efficient blood pressure reduction of at least 20% of the baseline level. Blood pressure changes were similar when the agent was administered in doses of 1.5 or 3 mg/kg. At 6-8 minutes after the drug was injected, there was a maximal decrease in blood pressure, then its gradual rise and stabilization at a lower level than the baseline one within the following 8 hours. There were no significant differences in the magnitude of a blood pressure reduction after administration of 1.5 and 3 mg/kg. CONCLUSION. The findings suggest that the dinitrosyl iron complex is highly effective in treating uncomplicated HC. The antihypertensive effect of the drug persists for 8 hours after its injection, which is very important during prehospital therapy. The drug is well tolerated by patients and causes an insignificant number of side effects.
Full Text
##article.viewOnOriginalSite##About the authors
A Iu Gosteev
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва121552 Москва, ул. 3-я Черепковская, д. 15А
A V Zorin
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
O V Rodnenkov
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
A G Dragnev
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
E I Chazov
ФГБУ "Российский кардиологический научно-производственный комплекс" Минздрава России, Москва
References
- Heart disease and Stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2-e220.
- Борьба с артериальной гипертонией. Доклад Комитета экспертов ВОЗ. Всемирная организация здравоохранения. Женева 1996.
- Чазова И.Е., Ощепкова Е.В., Чихладзе Н.М. Артериальная гипертония (принципы диагностики и лечения). Пособие для врачей. М 2005.
- Allam M.F., Arjona O. Health promotion or pharmacological treatment for chronic diseases? J Prev Med Hyg 2013; 54 (1): 11-13.
- Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001; 33 (11): 1897-1918.
- Degoute C.S. Controlled hypotension: a guide to drug choice. Drugs 2007; 67 (7): 1053-1076.
- Lakomkin V.L., Vanin A.F., Timoshin A.A. et al. Long-lasting hypotensive action of stable preparations of dinitrosyl-iron complexes with thiol-containing ligands in conscious normotensive and hypertensive rats. Nitric Oxide 2007; 16 (4): 413-418.
- Лакомкин В.Л., Студнева И.М., Писаренко О.И. и др. Функция и энергетическое состояние изолированного сердца крыс со спонтанной гипертензией. Кардиология 2000; 8: 53-61.
- Chazov E.I., Rodnenkov O.V., Zorin A.V. et al. Hypotensive effect of Oxacom containing a dinitrosyl iron complex with glutathione: animal studies and clinical trials on healthy volunteers. Nitric Oxide 2012; 26 (3): 148-156.
- Шумаев К.Б., Ванин А.Ф., Лакомкин В.Л. и др. Участие активных форм кислорода в модуляции гипотензивного эффекта динитрозильных комплексов железа. Кардиол вестн 2007; 2: 31-37.
- Голиков А.П. Кризы при гипертонической болезни: вчера и сегодня. Артериальная гипертензия 2004; 10: 147-151.
- Терещенко С.Н. Гипертонические кризы: диагностика и лечение. В кн.: Е.И. Чазов, И.Е. Чазова (ред.). Руководство по артериальной гипертонии. М 2005; 677-689.
- Laragh's L. Lesson XXV: How to Mechanistically Diagnose and Correctly Treat a Hypertensive Crisis AJH - September 2001; 14: 9.
- World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommittee. Hypertension 1999; 17: 151-183.
- Диагностика и лечение артериальной гипертензии. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов. Кардиоваск тер и проф 2008; 7 (6). Приложение 2.
- Терещенко C.H. Гипертонические кризы, современные принципы терапии. Системные гипертензии 2004; 6 (2): 42-46.
- Кобалава Ж.Д., Гудков К.М. Гипертонические кризы: существуют ли реальные противоречия в классификации и лечении? Сердце 2003; 2 (3): 116-127.
- Manchia G., De Backer G., Dominiczak A. et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-1187.
- Jones D., Hall J. Hypertension: pathways to success. Hypertension 2008; 51: 1249-1251.
- Chambanian A.V., Bakris G.L., Black H.R. et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: The JNC 7 report. JAMA 2003; 289: 2560-2572.
- Blumenfeld J.D., Laragh J.H. Management of hypertensive crises: the scientific basis for treatment decisions. AJH 2001; 14: 1154-1167.
